Genomics of racial and ethnic disparities in childhood acute lymphoblastic leukemia

Cancer

Volumn 120, Issue 7, 2014, Pages 955-962

  Lim, Joshua Yew Suang ^a,b   Bhatia, Smita ^c   Robison, Leslie L ^a   Yang, Jun J ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c Department of Population Sciences Duarte ^*  (United States)

Author keywords

childhood; disparity; ethnicity; genomics; leukemia; race

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BCR ABL PROTEIN; GLUTATHIONE TRANSFERASE M1; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR RUNX1;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER INCIDENCE; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CHILDHOOD LEUKEMIA; CHROMOSOME ABERRATION; ETHNIC DIFFERENCE; ETHNICITY; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC VARIABILITY; GENOMICS; GENOTYPE; HEALTH CARE DISPARITY; HEREDITY; HUMAN; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

CHILDHOOD; DISPARITY; ETHNICITY; GENOMICS; LEUKEMIA; RACE;

CHILD; ETHNIC GROUPS; GENOMICS; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SURVIVAL RATE;

EID: 84899422159     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28531     Document Type: Review

References (69)

1. Inaba H, Greaves M, Mullighan CG,. Acute lymphoblastic leukaemia. Lancet. 2013; 381: 1943-1955.
2. Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009; 360: 2730-2741.
3. Pui CH, Mullighan CG, Evans WE, Relling MV,. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood. 2012; 120: 1165-1174.
4. Dores GM, Devesa SS, Curtis RE, Linet MS, Morton LM,. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood. 2012; 119: 34-43.
5. Linabery AM, Ross JA,. Trends in childhood cancer incidence in the US (1992-2004). Cancer. 2008; 112: 416-432.
6. Bhatia S, Sather HN, Heerema NA, Trigg ME, Gaynon PS, Robison LL,. Racial and ethnic differences in survival of children with acute lymphoblastic leukemia. Blood. 2002; 100: 1957-1964.
7. Kadan-Lottick NS, Ness KK, Bhatia S, Gurney JG,. Survival variability by race and ethnicity in childhood acute lymphoblastic leukemia. JAMA. 2003; 290: 2008-2014.
8. Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the Children's Oncology Group. J Clin Oncol. 2012; 30: 1663-1669.
9. Chow EJ, Puumala SE, Mueller BA, et al. Childhood cancer in relation to parental race and ethnicity: a 5-state pooled analysis. Cancer. 2010; 116: 3045-3053.
10. Pollock BH, DeBaun MR, Camitta BM, et al. Racial differences in the survival of childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study. J Clin Oncol. 2000; 18: 813-823.
11. Mullighan CG,. Molecular genetics of B-precursor acute lymphoblastic leukemia. J Clin Invest. 2012; 122: 3407-3415.
12. Pui CH, Carroll WL, Meshinchi S, Arceci RJ,. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011; 29: 551-565.
13. Figueroa ME, Chen SC, Andersson AK, et al. Integrated genetic and epigenetic analysis of childhood acute lymphoblastic leukemia. J Clin Invest. 2013; 123: 3099-3111.
14. Taylor KH, Kramer RS, Davis JW, et al. Ultradeep bisulfite sequencing analysis of DNA methylation patterns in multiple gene promoters by 454 sequencing. Cancer Res. 2007; 67: 8511-8518.
15. Schafer E, Irizarry R, Negi S, et al. Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting. Blood. 2010; 115: 4798-4809.
16. Bamshad M, Wooding S, Salisbury BA, Stephens JC,. Deconstructing the relationship between genetics and race. Nat Rev Genet. 2004; 5: 598-609.
17. Bloche MG,. Health care disparities-science, politics, and race. N Engl J Med. 2004; 350: 1568-1570.
18. Ramachandran S, Deshpande O, Roseman CC, Rosenberg NA, Feldman MW, Cavalli-Sforza LL,. Support from the relationship of genetic and geographic distance in human populations for a serial founder effect originating in Africa. Proc Natl Acad Sci U S A. 2005; 102: 15942-15947.
19. Li JZ, Absher DM, Tang H, et al. Worldwide human relationships inferred from genome-wide patterns of variation. Science. 2008; 319: 1100-1104.
20. Mao X, Bigham AW, Mei R, et al. A genomewide admixture mapping panel for Hispanic/Latino populations. Am J Hum Genet. 2007; 80: 1171-1178.
21. Price AL, Patterson N, Yu F, et al. A genomewide admixture map for Latino populations. Am J Hum Genet. 2007; 80: 1024-1036.
22. Wang S, Lewis CM, Jakobsson M, et al. Genetic variation and population structure in Native Americans [serial online]. PLoS Genet. 2007; 3: e185.
23. National Cancer Institute. SEER Cancer Statistics Review, 1975-2006. 2009. Available at: http://seer.cancer.gov/csr/1975-2006/. Accessed July 22, 2013.
24. Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D,. GLOBOCAN 2000, Cancer Incidence and Mortality Worldwide. 2001. Available at: http://www-dep.iarc.fr/globocan/globocan.htm. Accessed March 6, 2012.
25. Pui CH, Sandlund JT, Pei D, et al. Results of therapy for acute lymphoblastic leukemia in black and white children. JAMA. 2003; 290: 2001-2007.
26. Aldrich MC, Zhang L, Wiemels JL, et al. Cytogenetics of Hispanic and white children with acute lymphoblastic leukemia in California. Cancer Epidemiol Biomarkers Prev. 2006; 15: 578-581.
27. Yang JJ, Cheng C, Devidas M, et al. Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet. 2011; 43: 237-241.
28. Hasle H, Clemmensen IH, Mikkelsen M,. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet. 2000; 355: 165-169.
29. Mullighan CG, Collins-Underwood JR, Phillips LA, et al. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet. 2009; 41: 1243-1246.
30. Vijayakrishnan J, Houlston RS,. Candidate gene association studies and risk of childhood acute lymphoblastic leukemia: a systematic review and meta-analysis. Haematologica. 2010; 95: 1405-1414.
31. Koppen IJ, Hermans FJ, Kaspers GJ,. Folate related gene polymorphisms and susceptibility to develop childhood acute lymphoblastic leukaemia. Br J Haematol. 2010; 148: 3-14.
32. Urayama KY, Chokkalingam AP, Metayer C, et al. HLA-DP genetic variation, proxies for early life immune modulation and childhood acute lymphoblastic leukemia risk. Blood. 2012; 120: 3039-3047.
33. Chang JS, Wiemels JL, Chokkalingam AP, et al. Genetic polymorphisms in adaptive immunity genes and childhood acute lymphoblastic leukemia. Cancer Epidemiol Biomarkers Prev. 2010; 19: 2152-2163.
34. Hosking FJ, Leslie S, Dilthey A, et al. MHC variation and risk of childhood B-cell precursor acute lymphoblastic leukemia. Blood. 2011; 117: 1633-1640.
35. Trevino LR, Yang W, French D, et al. Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet. 2009; 41: 1001-1005.
36. Papaemmanuil E, Hosking FJ, Vijayakrishnan J, et al. Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. Nat Genet. 2009; 41: 1006-1010.
37. Xu H, Yang W, Perez-Andreu V, et al. Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations. J Natl Cancer Inst. 2013; 105: 733-742.
38. Sherborne AL, Hosking FJ, Prasad RB, et al. Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. Nat Genet. 2010; 42: 492-494.
39. Lahoud MH, Ristevski S, Venter DJ, et al. Gene targeting of Desrt, a novel ARID class DNA-binding protein, causes growth retardation and abnormal development of reproductive organs. Genome Res. 2001; 11: 1327-1334.
40. Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009; 360: 470-480.
41. Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007; 446: 758-764.
42. Yamanaka R, Kim GD, Radomska HS, et al. CCAAT/enhancer binding protein epsilon is preferentially up-regulated during granulocytic differentiation and its functional versatility is determined by alternative use of promoters and differential splicing. Proc Natl Acad Sci U S A. 1997; 94: 6462-6467.
43. Nakajima H, Watanabe N, Shibata F, Kitamura T, Ikeda Y, Handa M,. N-terminal region of CCAAT/enhancer-binding protein epsilon is critical for cell cycle arrest, apoptosis, and functional maturation during myeloid differentiation. J Biol Chem. 2006; 281: 14494-14502.
44. Akasaka T, Balasas T, Russell LJ, et al. Five members of the CEBP transcription factor family are targeted by recurrent IGH translocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Blood. 2007; 109: 3451-3461.
45. Prasad RB, Hosking FJ, Vijayakrishnan J, et al. Verification of the susceptibility loci on 7p12.2, 10q21.2, and 14q11.2 in precursor B-cell acute lymphoblastic leukemia of childhood. Blood. 2010; 115: 1765-1767.
46. Yang W, Trevino LR, Yang JJ, et al. ARID5B SNP rs10821936 is associated with risk of childhood acute lymphoblastic leukemia in blacks and contributes to racial differences in leukemia incidence. Leukemia. 2010; 24: 894-896.
47. Healy J, Richer C, Bourgey M, Kritikou EA, Sinnett D,. Replication analysis confirms the association of ARID5B with childhood B-cell acute lymphoblastic leukemia. Haematologica. 2010; 95: 1608-1611.
48. Pastorczak A, Gorniak P, Sherborne A, et al. Role of 657del5 NBN mutation and 7p12.2 (IKZF1), 9p21 (CDKN2A), 10q21.2 (ARID5B) and 14q11.2 (CEBPE) variation and risk of childhood ALL in the Polish population. Leukemia Res. 2011; 35: 1534-1536.
49. Walsh KM, de Smith AJ, Chokkalingam AP, et al. Novel childhood ALL susceptibility locus BMI1-PIP4K2A is specifically associated with the hyperdiploid subtype. Blood. 2013; 121: 4808-4809.
50. Xu H, Cheng C, Devidas M, et al. ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol. 2012; 30: 751-757.
51. Ellinghaus E, Stanulla M, Richter G, et al. Identification of germline susceptibility loci in ETV6-RUNX1-rearranged childhood acute lymphoblastic leukemia. Leukemia. 2012; 26: 902-909.
52. Orsi L, Rudant J, Bonaventure A, et al. Genetic polymorphisms and childhood acute lymphoblastic leukemia: GWAS of the ESCALE study (SFCE). Leukemia. 2012; 26: 2561-2564.
53. Eden T,. Aetiology of childhood leukaemia. Cancer Treat Rev. 2010; 36: 286-297.
54. Kinlen LJ,. Infective cause of childhood leukaemia. Lancet. 1989; 1: 378-379.
55. Greaves M,. Infection, immune responses and the aetiology of childhood leukaemia. Nat Rev. 2006; 6: 193-203.
56. Kinlen L,. Childhood leukaemia, nuclear sites, and population mixing. Br J Cancer. 2011; 104: 12-18.
57. Buffler PA, Kwan ML, Reynolds P, Urayama KY,. Environmental and genetic risk factors for childhood leukemia: appraising the evidence. Cancer Invest. 2005; 23: 60-75.
58. Spector LG, Ross JA, Robison LL, Bhatia S., Epidemiology and etiology. In:, Pui CH, ed. Childhood Leukemias. 3rd ed. New York: Cambridge University Press; 2012: 49-71.
59. Shu XO, Ross JA, Pendergrass TW, Reaman GH, Lampkin B, Robison LL,. Parental alcohol consumption, cigarette smoking, and risk of infant leukemia: a Children's Cancer Group study. J Natl Cancer Inst. 1996; 88: 24-31.
60. Linabery AM, Olshan AF, Gamis AS, et al. Exposure to medical test irradiation and acute leukemia among children with Down syndrome: a report from the Children's Oncology Group [serial online]. Pediatrics. 2006; 118: e1499-e1508.
61. Slater ME, Linabery AM, Spector LG, et al. Maternal exposure to household chemicals and risk of infant leukemia: a report from the Children's Oncology Group. Cancer Causes Control. 2011; 22: 1197-1204.
62. Pui CH, Boyett JM, Hancock ML, Pratt CB, Meyer WH, Crist WM,. Outcome of treatment for childhood cancer in black as compared with white children. The St Jude Children's Research Hospital experience, 1962 through 1992. JAMA. 1995; 273: 633-637.
63. Goggins WB, Lo FF,. Racial and ethnic disparities in survival of US children with acute lymphoblastic leukemia: evidence from the SEER database 1988-2008. Cancer Causes Control. 2012; 23: 737-743.
64. Roberts KG, Morin RD, Zhang J, et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell. 2012; 22: 153-166.
65. Den Boer ML, van Slegtenhorst M, De Menezes RX, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 2009; 10: 125-134.
66. Harvey RC, Mullighan CG, Chen IM, et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood. 2010; 115: 5312-5321.
67. Perez-Andreu V, Roberts KG, Harvey RC, et al. Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nat Genet. 2013; 45: 1494-1498.
68. Pappas G, Queen S, Hadden W, Fisher G,. The increasing disparity in mortality between socioeconomic groups in the United States, 1960 and 1986. N Engl J Med. 1993; 329: 03-109.
69. Bhatia S, Landier W, Shangguan M, et al. Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the Children's Oncology Group. J Clin Oncol. 2012; 30: 2094-2101.